ANTHROPOMETRY
|
Age (y)
|
64 ± 11
|
63 ± 11
|
68 ± 10
|
0.003
|
Sex (m)
|
292 (78%)
|
248 (76%)
|
44 (79%)
|
0.859
|
Body mass index
|
26 ± 4
|
26 ± 4
|
26 ± 4
|
0.300
|
CAD RISK FACTORS
|
Familiar history of CAD
|
170 (45%)
|
143 (45%)
|
27 (48%)
|
0.625
|
Smoking habit
|
220 (59%)
|
179 (56%)
|
41 (73%)
|
0.015
|
Diabetes
|
77 (21%)
|
66 (21%)
|
11 (20%)
|
0.867
|
Hypertension
|
218 (58%)
|
185 (58%)
|
33 (59%)
|
0.876
|
Hypercholesterolemia
|
214 (57%)
|
181 (57%)
|
33 (59%)
|
0.742
|
# risk factors
|
2.4 ± 1.1
|
2.4 ± 1.1
|
2.6 ± 1.1
|
0.159
|
CLINIC HISTORY
|
Previous CAD diagnosis
|
332 (88%)
|
277 (87%)
|
55 (98%)
|
0.012
|
Previous myocardial infarction
|
246 (65%)
|
202 (63%)
|
44 (79%)
|
0.025
|
NYHA classification (III class)
|
22 (6%)
|
11 (3%)
|
11 (20%)
|
<0.0001
|
Revascularization in the follow-up
|
79 (21%)
|
73 (23%)
|
6 (11%)
|
0.040
|
PHARMACOLOGICAL THERAPY
|
β-blockers
|
289 (77%)
|
448 (78%)
|
41 (73%)
|
0.483
|
Ca++−antagonist
|
76 (20%)
|
62 (19%)
|
14 (25%)
|
0.334
|
Nitrates
|
159 (42%)
|
136 (43%)
|
23 (41%)
|
0.842
|
Loop diuretics
|
135 (36%)
|
95 (30%)
|
40 (71%)
|
<0.0001
|
Aldosterone antagonist
|
51 (14%)
|
30 (9%)
|
21 (38%)
|
<0.0001
|
ACE-inhibitors/AT1-receptors antagonist
|
304 (81%)
|
257 (80%)
|
47 (84%)
|
0.526
|
ASA
|
319 (85%)
|
275 (86%)
|
44 (79%)
|
0.156
|
Statins
|
280 (75%)
|
240 (75%)
|
40 (71%)
|
0.572
|
Anticoagulant
|
33 (9%)
|
18 (6%)
|
15 (27%)
|
<0.0001
|
ECG
|
Heart rate (bpm)
|
65 ± 13
|
64 ± 12
|
73 ± 14
|
<0.0001
|
Non sinusal rhythm
|
12 (3%)
|
7 (2%)
|
5 (9%)
|
0.021
|
QRS duration (msec)
|
105 ± 21
|
103 ± 19
|
112 ± 27
|
0.022
|
QTc interval (msec)
|
425 ± 34
|
421 ± 32
|
447 ± 37
|
<0.0001
|
LV hypertrophy
|
58 (15%)
|
50 (14%)
|
8 (16%)
|
0.942
|
LBB block
|
59 (16%)
|
44 (14%)
|
15 (27%)
|
0.013
|
RBB block
|
16 (12%)
|
12 (12%)
|
4 (14%)
|
0.612
|
ST segment depression
|
46 (8%)
|
38 (7%)
|
8 (13%)
|
0.176
|
Negative T waves
|
184 (49%)
|
151 (47%)
|
33 (59%)
|
0.105
|
Q waves
|
164 (44%)
|
135 (42%)
|
29 (52%)
|
0.181
|
ECHOCARDIOGRAPHY
|
LV EDV (ml/m2)
|
59 ± 22
|
57 ± 20
|
74 ± 30
|
<0.0001
|
LV ESV (ml/m2)
|
31 ± 20
|
28 ± 16
|
49 ± 28
|
<0.0001
|
LV EF (%)
|
51 ± 13
|
53 ± 12
|
39 ± 15
|
<0.0001
|
LV WMSI
|
1.4 ± 0.5
|
1.4 ± 0.4
|
1.9 ± 0.5
|
<0.0001
|
LV mass (g)
|
188 ± 59
|
186 ± 57
|
202 ± 70
|
<0.0001
|
LV diastolic function (≥ pseudo-normal)
|
44 (12%)
|
25 (8%)
|
19 (34%)
|
<0.0001
|
Mitral regurgitation (≥ moderate)
|
56 (15%)
|
36 (11%)
|
20 (36%)
|
<0.0001
|
Pulmonary hypertension
|
34 (9%)
|
19 (6%)
|
15 (27%)
|
<0.0001
|
RVIT dilatation
|
17 (5%)
|
12 (4%)
|
5 (9%)
|
0.085
|
RV dysfunction
|
38 (10%)
|
28 (9%)
|
10 (18%)
|
0.037
|
LATE GADOLINIUM ENHANCEMENT
|
Total burden (% of LV mass)
|
13 ± 15
|
10 ± 12
|
28 ± 22
|
<0.0001
|
Spatial extent (% of LV surface)
|
22 ± 22
|
18 ± 19
|
42 ± 29
|
<0.0001
|
Max transmural extent (% of wall thickness)
|
55 ± 39
|
51 ± 39
|
73 ± 39
|
<0.0001
|